Associations between persistent symptoms after mild COVID-19 and long-term health status, quality of life, and psychological distress.
COVID-19
COVID-19 outcomes
long-COVID
post-COVID conditions
post-acute sequalae of COVID-19 (PASC)
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
28
02
2022
received:
29
01
2022
accepted:
01
03
2022
pubmed:
30
3
2022
medline:
11
6
2022
entrez:
29
3
2022
Statut:
ppublish
Résumé
We sought to assess whether persistent COVID-19 symptoms beyond 6 months (Long-COVID) among patients with mild COVID-19 is associated with poorer health status, quality of life, and psychological distress. This was a multicenter prospective cohort study that included adult outpatients with acute COVID-19 from eight sites during 2-week sampling periods from April 1 and July 28, 2020. Participants were contacted 6-11 months after their first positive SARS-CoV-2 to complete a survey, which collected information on the severity of eight COVID-19 symptoms using a 4-point scale ranging from 0 (not present) to 3 (severe) at 1 month before COVID-19 (pre-illness) and at follow-up; the difference for each was calculated as an attributable persistent symptom severity score. A total attributable persistent COVID-19 symptom burden score was calculated by summing the attributable persistent severity scores for all eight symptoms. Outcomes measured at long-term follow-up comprised overall health status (EuroQol visual analogue scale), quality of life (EQ-5D-5L), and psychological distress (Patient Health Questionnaire-4). The association between the total attributable persistent COVID-19 burden score and each outcome was analyzed using multivariable proportional odds regression. Of the 2092 outpatients with COVID-19, 436 (21%) responded to the survey. The median (IQR) attributable persistent COVID-19 symptom burden score was 2 (0, 4); higher scores were associated with lower overall health status (aOR 0.63; 95% CI: 0.57-0.69), lower quality of life (aOR: 0.65; 95%CI: 0.59-0.72), and higher psychological distress (aOR: 1.40; 95%CI, 1.28-1.54) after adjusting for age, race, ethnicity, education, and income. In participants with mild acute COVID-19, the burden of persistent symptoms was significantly associated with poorer long-term health status, poorer quality of life, and psychological distress.
Sections du résumé
BACKGROUND
We sought to assess whether persistent COVID-19 symptoms beyond 6 months (Long-COVID) among patients with mild COVID-19 is associated with poorer health status, quality of life, and psychological distress.
METHODS
This was a multicenter prospective cohort study that included adult outpatients with acute COVID-19 from eight sites during 2-week sampling periods from April 1 and July 28, 2020. Participants were contacted 6-11 months after their first positive SARS-CoV-2 to complete a survey, which collected information on the severity of eight COVID-19 symptoms using a 4-point scale ranging from 0 (not present) to 3 (severe) at 1 month before COVID-19 (pre-illness) and at follow-up; the difference for each was calculated as an attributable persistent symptom severity score. A total attributable persistent COVID-19 symptom burden score was calculated by summing the attributable persistent severity scores for all eight symptoms. Outcomes measured at long-term follow-up comprised overall health status (EuroQol visual analogue scale), quality of life (EQ-5D-5L), and psychological distress (Patient Health Questionnaire-4). The association between the total attributable persistent COVID-19 burden score and each outcome was analyzed using multivariable proportional odds regression.
RESULTS
Of the 2092 outpatients with COVID-19, 436 (21%) responded to the survey. The median (IQR) attributable persistent COVID-19 symptom burden score was 2 (0, 4); higher scores were associated with lower overall health status (aOR 0.63; 95% CI: 0.57-0.69), lower quality of life (aOR: 0.65; 95%CI: 0.59-0.72), and higher psychological distress (aOR: 1.40; 95%CI, 1.28-1.54) after adjusting for age, race, ethnicity, education, and income.
CONCLUSIONS
In participants with mild acute COVID-19, the burden of persistent symptoms was significantly associated with poorer long-term health status, poorer quality of life, and psychological distress.
Identifiants
pubmed: 35347854
doi: 10.1111/irv.12980
pmc: PMC9111447
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
680-689Subventions
Organisme : NHLBI NIH HHS
ID : K23 HL153584
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002369
Pays : United States
Organisme : CDC HHS
ID : 75D30120C07637
Pays : United States
Informations de copyright
© 2022 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Références
Value Health. 2019 Aug;22(8):931-941
pubmed: 31426935
JAMA. 2021 Nov 23;326(20):2043-2054
pubmed: 34734975
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Ann Med. 2001 Jul;33(5):337-43
pubmed: 11491192
Chest. 2021 Mar;159(3):949-958
pubmed: 33159907
Ann Intern Med. 2021 Sep;174(9):1252-1260
pubmed: 34224254
Pharmacoeconomics. 1998 Apr;13(4):421-33
pubmed: 10178666
Influenza Other Respir Viruses. 2022 Jul;16(4):680-689
pubmed: 35347854
MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):993-998
pubmed: 32730238
MMWR Morb Mortal Wkly Rep. 2020 Sep 11;69(36):1258-1264
pubmed: 32915165
Lancet Psychiatry. 2021 May;8(5):416-427
pubmed: 33836148
MMWR Morb Mortal Wkly Rep. 2020 Nov 06;69(44):1648-1653
pubmed: 33151918
Qual Life Res. 2016 Jun;25(6):1585-96
pubmed: 26714699
Ann Clin Transl Neurol. 2021 May;8(5):1073-1085
pubmed: 33755344
Ir J Med Sci. 2021 May;190(2):461-468
pubmed: 32894436
Psychosomatics. 2009 Nov-Dec;50(6):613-21
pubmed: 19996233
Psychiatry Res. 2020 Oct;292:113297
pubmed: 32707218
Clin Infect Dis. 2022 Jun 08;:
pubmed: 35675695
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
JAMA. 2021 May 18;325(19):2015-2016
pubmed: 33825846
J Infect. 2020 Dec;81(6):e4-e6
pubmed: 32853602
J Neurovirol. 2021 Feb;27(1):191-195
pubmed: 33528824
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937
Sci Rep. 2021 Aug 9;11(1):16144
pubmed: 34373540
JAMA Netw Open. 2021 Feb 1;4(2):e210830
pubmed: 33606031
Respir Care. 2015 Jan;60(1):88-95
pubmed: 25336531